TRIB - Trinity Biotech plc (TRIB) Q4 2023 Earnings Call Transcript
2024-04-04 15:03:06 ET
Trinity Biotech plc (TRIB)
Q4 2023 Earnings Conference Call
April 04, 2024 08:00 a.m. ET
Company Participants
John Gillard - Chief Executive Officer
Des Fitzgerald - Chief Financial Officer
Eric Ribner - Investor Relations
Conference Call Participants
Jim Sidoti - Sidoti & Company
Paul Nouri - Noble
Presentation
Operator
Greetings! Welcome to the Trinity Biotech’s Fourth Quarter and Full Year 2023 Earnings Conference Call. At this time, all participants are in a listen only mode. A question and answer session will follow the formal presentation. [Operator Instructions]. Please note that this conference is being recorded.
At this time I’ll now turn the conference over to Eric Ribner, with Investor Relations. Eric, you may now begin.
Eric Ribner
Good morning everyone. And thank you for joining us on today call. Before we begin, please note that statements made during this presentation may be deemed forward-looking statements within the meaning of Federal Securities Laws. These statements are subject to known and unknown risks and uncertainties that may cause actual events to differ from those expressed or implied in such statements.
These risks include, but are not limited to those set forth in the risk factor statement in the company's annual report on Form 20-F filed with the Securities and Exchange Commission. Trinity Biotech undertakes no obligation to publicly advise, update or revise these forward-looking statements to reflect events or circumstances after today, or the occurrence of unanticipated events.
And with that, I’ll turn the call over to John Gillard, CEO.
John Gillard
Thank you, Eric. Good morning everyone. And thank you for joining today's call. We really do appreciate you taking the time. This morning I will take you through some key business updates, including new financial guidance, our progress in our recently acquired biosensor business, and our comprehensive transformation plan, that I set out to investors in early March at the Emerging Growth Conference. I will then hand you over to Des to bring you through the financial results for Q4 and fiscal year 2023.
Right now, Trinity Biotech is an experience diagnostic company that under new leadership and with fresh thinking plans to transform its existing business into a high-performing cash-generative enterprise. This morning we are pleased to introduce financial guidance which is predicated solely on growth from the existing businesses, including haemoglobin and HIV testing, and planned improvements to operating margins. ...
Trinity Biotech plc (TRIB) Q4 2023 Earnings Call Transcript